Psoriasis in association with prolactinoma: three cases.
We report three women with plaque-type psoriasis in whom increase in severity and extent of the skin lesions correlated with the development of a prolactinoma. In all three patients, administration of bromocriptine, a dopamine agonist that suppresses the secretion of prolactin, improved the therapeutic response of the psoriasis. To our knowledge, there are no reports of an association between psoriasis and prolactinoma. In recent years it has become apparent that prolactin plays an important part in the immune reactions and exerts a proliferative effect on human keratinocytes. We, therefore, discuss the part that prolactin may play in the pathogenesis of psoriasis.
Sánchez Regaña
M
M
Department of Dermatology, Hospital Sagrado Corazón, University of Barcelona, C/París 83-87 5th floor, 08029 Barcelona, Spain. ez.reg@teleline.es
Umbert Millet
P
P
D000328:Adult; D005260:Female; D006801:Humans; D010257:Paraneoplastic Syndromes / Q000209:etiology*; D010911:Pituitary Neoplasms / Q000150:complications*; D011388:Prolactin / Q000502:physiology; D015175:Prolactinoma / Q000150:complications*; D011565:Psoriasis / Q000209:etiology*
D011388:Prolactin